Patients with cancer are at risk of developing venous thromboembolism ([VTE]; deep venous thrombosis, and pulmonary embolism). Although vitamin K antagonists had originally been used to treat VTE in these patients, low-molecular-weight heparins (LMWH) have been shown to be more effective and safe for patients with cancer-associated thrombosis. In cancer patients with advanced disease where curative therapy is no longer the intent of treatment, continued anticoagulation for VTE for palliative purposes continues to remain a controversial topic as no large randomized trials have been conducted to guide clinicians in this setting. This review summarizes the data available for treating VTE in cancer patients receiving palliative services.
Lee A.Thrombosis and cancer: the role of screening for occult cancer and recognizing the underlying biological mechanisms. Hematology Am Soc Hematol Educ Program. 2006:438-443. 2. Blom JW, Doggen CJM, Osanto S., Rosendaal FRMalignancies, prothrombotic mutations, and the risk of venous thrombosis. J AMA. 2005;293(6):715-722.
2.
Heit J., Silverstein M., Mohr D., Petterson T., O’Fallon WM, Melton LJ 3rd.Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-815.
3.
Prandoni P., Lensing A., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis . Blood. 2002;100(10):3484-3488.
4.
Linkins L.Management of venous thromboembolism in patients with cancer: role of dalteparin . Vasc Health Risk Manag. 2008 ; 4(2):279-287.
5.
Johnson M., Sproule M., Paul J.The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol (R Coll Radiol) . 1999;11(2):105-110.
6.
Blom J., Vanderschoot J., Oostindiër M., Osanto S., Meer FVD, Rosendaal F.Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. JThromb Haemost.2006;4(3):529-535.
7.
Chew H., Wun T., Harvey D., Zhou H., White R.Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006 ;166(4): 458-464.
8.
Cronin C., Lohan D., Keane M., Roche C., Murphy J.Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT. Am J Roentgenol. 2007; 189(1):162-170.
9.
Lee A., Levine M., Baker R., et al, Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
10.
Monreal M., Zacharski L., Jiménez J., Roncales J., Vilaseca B.Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. J Thromb Haemost. 2004; 2(8):1311-1315.
11.
Hull R., Pineo G., Brant R., et al, LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062-1072.
12.
Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729-1735.
13.
Deitcher S. , Kessler C., Merli G., Rigas J., Lyones R., Fareed J.Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period . Clin Appl Thromb Hemost. 2006;12(4):389-396.
14.
Aujesky D., Smith K., Cornuz J., Roberts M.Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism. Thromb Haemost. 2005;93(3):592-599.
15.
Dranitsaris G., Vincent M., Crowther M.Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Pharmacoeconomics. 2006;24(6):593-607.
16.
Noble S., Hood K., Finlay I.The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. Palliat Med.2007;21(6):473-476.
17.
Noble S., Finlay I.Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study . Palliat Med. 2005;19(3):197-201.
18.
Soto-Cárdenas M., Pelayo-García G., Rodríguez-Camacho A., Segura-Fernández E., Mogollo-Galván A., Giron-Gonzalez J.Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice. Palliat Med. 2008;22(8):965-968.
19.
Noble S., Shelley M., Coles B., Wiliams S., Wilcock A., Johnson M.Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol. 2008 ;9(6):577-584.
